Remeditex Ventures LLC 4
4 · Menlo Therapeutics, Inc. · Filed Jan 29, 2018
Insider Transaction Report
Form 4
Remeditex Ventures LLC
10% Owner
Transactions
- Conversion
Common Stock
2018-01-29+2,650→ 1,585,504 total - Purchase
Common Stock
2018-01-25$17.00/sh+100,000$1,700,000→ 1,582,854 total - Conversion
Common Stock
2018-01-29+304,576→ 2,761,663 total - Conversion
Series B Preferred Stock
2018-01-29−2,351,097→ 0 total→ Common Stock (871,583 underlying) - Conversion
Series A Preferred Stock
2018-01-29−7,150→ 0 total→ Common Stock (2,650 underlying) - Conversion
Series C Preferred Stock
2018-01-29−821,596→ 0 total→ Common Stock (304,576 underlying) - Conversion
Common Stock
2018-01-29+871,583→ 2,457,087 total
Footnotes (1)
- [F1]Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.